Skip to main content

Table 1 Descriptive data at baseline (T0) for 950 patients and at 5-year follow up (T5) in 726 of the patients diagnosed with early rheumatoid arthritis

From: Co-morbidity in patients with early rheumatoid arthritis - inflammation matters

Characteristics Values
Age at onset of symptoms, years 55.6 (14.4)
Female/male, T0 649/301 (68.3/31.7)
Duration of symptoms at T0, months 6.7 (3.5)
RF+ 75.3
ANA+ 22.0
ACPA+ 69.0
HLA-SE+ 58.0
Disease activity and severity at T0  
ESR, mm/h 30.1 (23.2)
CRP, mg/L 20.7 (24.3)
HAQ 0.86 (0.6)
Tender joint count 6.4 (5.7)
Swollen joint count 7.0 (5.2)
VAS pain, mm 43.4 (25.7)
VAS global, mm 44.4 (25.7)
AUC DAS28, 6 months 25.1 (7.2)
AUC DAS28, 12 months 46.2 (13.4)
AUC DAS28, 24 months 86.5 (25.6)
Ex-RA ≤ T5 4.9
Nodules ≤ T5 16.4
Smoking ever, T0 65.8
Treatments  
DMARDs within 3 months after T0 90.1
DMARDs ever ≤ T5 97.8
Methotrexate ever ≤ T5 86.9
Biological treatment ever ≤ T5 16.5
Time without DMARDs from symptom onset, months 6.8 (4.9)
Time without DMARDs T0–T5, months 8.4 (15.7)
NSAIDs ever ≤ T5 84.0
Cox-2 inhibitors ever ≤ T5 26.5
Corticosteroids T0–T5, months 22.2 (23.8)
Corticosteroids ever ≤ T5 71.0
  1. Mean(SD), number or percent. RF rheumatoid factor, ANA anti-nuclear antibody, ACPA anti-citrullinated protein/peptide antibody (analyzed as anti-CCP2), HLE-SE human leucocyte antigen-shared epitope, ESR erythrocyte sedimentation rate, CRP C-reactive protein, HAQ health assessment questionnaire, AUC area under curve, DAS28 disease activity score in 28 joints, Ex-RA extra articular manifestations of RA, DMARDs disease modifying anti-rheumatic drugs, NSAIDs non-steroid anti-inflammatory drugs, Cox-2 cyclo oxygenase 2inhibitors